Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer

Cancer Science

Volumn 98, Issue 12, 2007, Pages 1902-1913

  Mano, Yuria ^a   Takahashi, Koji ^a   Ishikawa, Nobuhisa ^a   Takano, Atsushi ^a   Yasui, Wataru ^b   Inai, Kouki ^c   Nishimura, Hitoshi ^d   Tsuchiya, Eiju ^e   Nakamura, Yusuke ^a   Daigo, Yataro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON MURINE LEUKEMIA ONCOVIRUS HOMOLOG 1 PROTEIN; BINDING PROTEIN; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR RECEPTOR 1 ONCOGENE PARTNER PROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WERNER HELICASE INTERACTING PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL MOTILITY; CONTROLLED STUDY; DISEASE MARKER; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; SURVIVAL TIME;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; ORGAN SPECIFICITY; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 35548992255     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00610.x     Document Type: Article

References (48)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001; 51: 15-36.
2. Sozzi G. Molecular biology of lung cancer. Eur J Cancer 2001; 37 (Suppl 7): S63-73.
3. Kelly K, Crowley J, Bunn PA et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-18.
4. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
5. Kikuchi T, Daigo Y, Katagiri T et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003; 22: 2192-205.
6. Kikuchi T, Daigo Y, Ishikawa N et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 2006; 28: 799-805.
7. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003; 1: 485-99.
8. Kakiuchi S, Daigo Y, Ishikawa N et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004; 13: 3029-43.
9. Ochi K, Daigo Y, Katagiri T et al. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 2004; 24: 647-55.
10. Yamabuki T, Daigo Y, Kato T et al. Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 2006 June; 28: 1375-84.
11. Taniwaki M, Daigo Y, Ishikawa N et al. Gene expression profiles of small-cell lung cancers: Molecular signatures of lung cancer. Int J Oncol 2006; 29: 567-75.
12. Saito-Hisaminato A, Katagiri T, Kakiuchi S, Nakamura T, Tsunoda T, Nakamura Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 2002; 9: 35-45.
13. Ochi K, Daigo Y, Katagiri T et al. Expression profiles of two types of human knee-joint cartilage. J Hum Genet 2003; 48: 177-82.
14. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003; 63: 7038-41.
15. Suzuki C, Daigo Y, Ishikawa N et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2005; 65: 11 314-25.
16. Suzuki C, Takahashi K, Hayama S et al. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol CancerTher 2007; 6: 542-51.
17. Ishikawa N, Daigo Y, Yasui W et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004; 10: 8363-70.
18. Ishikawa N, Daigo Y, Taniwaki M et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005; 65: 9176-84.
19. Ishikawa N, Daigo Y, Takano A et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006; 97: 737-45.
20. Kato T, Daigo Y, Hayama S et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 2005; 65: 5638-46.
21. Kato T, Hayama S, Yamabuki Y et al. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res 2007; 13: 434-42.
22. Kato T, Sato N, Hayama S et al. Activation of HJURP (Holliday Junction-Recognizing Protein) involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007 Sep 6; [Epub ahead of print].
23. Furukawa C, Daigo Y, Ishikawa N et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 2005; 65: 7102-10.
24. Takahashi K, Furukawa C, Takano A et al. The neuromedin u-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 2006; 66: 9408-19.
25. Hayama S, Daigo Y, Kato T et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006; 66: 10 39-48.
26. Hayama S, Daigo Y, Yamabuki T et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res 2007; 67: 4113-22.
27. Yamabuki T, Takano A, Hayama S et al. Dickkopf-1 as a Novel Serologic and Prognostic Biomarker for Lung and Esophageal Carcinomas. Cancer Res 2007; 67: 2517-25.
28. Popovici C, Zhang B, Gregoire MJ et al. The t (6;8) (q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 1999; 93: 1381-9.
29. Guasch G, Ollendorff V, Borg JP, Birnbaum D, Pebusque MJ. 8p12 stem cell myeloproliferative disorder: The FOP-fibroblast growth factor receptor 1 fusion protein of the t (6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways. Mol Cell Biol 2001; 21: 8129-42.
30. Guasch G, Delaval B, Arnoulet C et al. FOP-FGFR1 tyrosine kinase, the product of a t (6;8) translocation, induces a fatal myeloproliferative disease in mice. Blood 2004; 103: 309-12.
31. Kawabe Y, Branzei D, Hayashi T et al. A novel protein interacts with the Werner's syndrome gene product physically and functionally. J Biol Chem 2001; 276: 20 364-9.
32. Kawabe Y, Seki M, Seki T et al. Covalent modification of the Werner's syndrome gene product with the ubiquitin-related protein, SUMO-1. J Biol Chem 2000; 275: 20 963-6.
33. Hishida T, Iwasaki H, Ohno T, Morishita T, Shinagawa H. A yeast gene, MGS1, encoding a DNA-dependent AAA(+) ATPase is required to maintain genome stability. Proc Natl Acad Sci USA 2001; 98: 8283-9.
34. Branzei D, Seki M, Onoda F, Enomoto T. The product of Saccharomyces cerevisiae WHIP/MGS1, a gene related to replication factor C genes, interacts functionally with DNA polymerase delta. Mol Genet Genomics 2002; 268: 371-86.
35. Tsurimoto T, Shinozaki A, Yano M, Seki M, Enomoto T. Human Werner helicase interacting protein 1 (WRNIP1) functions as a novel modulator for DNA polymerase delta. Genes Cells 2005; 10: 13-22.
36. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological Typing of Lung and Pleural Tumors: World Health Organization International Histological Classification of Tumors, 3rd edn. Berlin: Springer, 1999.
37. Chin SF, Daigo Y, Huang HE et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003; 56: 275-9.
38. Callagy G, Cattaneo E, Daigo Y et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003; 12: 27-34.
39. Callagy G, Pharoah P, Chin SF et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005; 205: 388-96.
40. Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000; 19: 5643-50.
41. Pendergast AM. The Abl family kinases: Mechanisms of regulation and signaling. Adv Cancer Res 2002; 85: 51-100.
42. Emes RD, Ponting CP. A new sequence motif linking lissencephaly, Treacher Collins and oral-facial-digital type 1 syndromes, microtubule dynamics and cell migration. Hum Mol Genet 2001; 10: 2813-20.
43. Umeda M, Nishitani H, Nishimoto T. A novel nuclear protein, Twa1, and Muskelin comprise a complex with RanBPM. Gene 2003; 303: 47-54.
44. Delaval B, Letard S, Lelievre H et al. Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome. Cancer Res 2005; 65: 7231-40.
45. Gangloff S, McDonald JP, Bendixen C, Arthur L, Rothstein R. The yeast type I topoisomerase Top3 interacts with Sgs1, a DNA helicase homolog: A potential eukaryotic reverse gyrase. Mol Cell Biol 1994; 14: 8391-8.
46. Wen ST, Jackson PK, Van Etten RA. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J 1996; 15: 1583-95.
47. Theis S, Roemer K. c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors. Oncogene 1998; 17: 557-64.
48. Cong F, Goff SP. c-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation. Proc Natl Acad Sci USA 1999; 96: 13 819-24.